— Know what they know.
Not Investment Advice

ANTX NASDAQ

AN2 Therapeutics, Inc.
1W: +8.4% 1M: -22.9% 3M: -23.1% YTD: +247.8% 1Y: +229.9% 3Y: -74.2%
$3.86
+0.23 (+6.34%)
 
Weekly Expected Move ±11.9%
$3 $3 $4 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 30 · $145.7M mcap · 22M float · 1.31% daily turnover · Short 74% of daily vol
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 6.39.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Income Trends

Revenue
$0 +0.0% ▲
Gross Profit
$0 +0.0% ▲
Operating Income
-$38M +30.1% ▲
Net Income
-$35M +31.5% ▲
EPS (Diluted)
$-1.16 +32.6% ▲
EBITDA
-$38M -1278.8% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$0$0$0$0$0
YoY Growth+0.0%+0.0%+0.0%+0.0%+0.0%
Cost of Revenue$0$77K$0$0$0
Gross Profit$0-$77K$0$0$0
Gross Margin—————
R&D Expenses$17M$30M$55M$40M$25M
SG&A Expenses$5M$13M$15M$14M$13M
Operating Expenses$22M$42M$70M$55M$38M
Operating Income-$22M-$42M-$70M-$55M-$38M
Operating Margin—————
Interest Expense$0$514K$0$0$0
Income Before Tax-$22M-$41M-$65M-$51M-$35M
Tax Expense$0$0$0$0$0
Net Income-$22M-$41M-$65M-$51M-$35M
Net Margin—————
EPS (Diluted)$-1.50$-2.79$-2.74$-1.72$-1.16
EBITDA-$22M-$41M$5M$3M-$38M
Shares Outstanding19M15M24M30M30M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms